Efficacy and safety of thrice weekly DOTS in tuberculosis patients with and without HIV co-infection: an observational study

Table 8 Treatment outcome at 24 months follow-up*

TREATMENT OUTCOME number (percent)	HIV + (n = 102)	HIV- (n = 109)	P-value
Treatment success ⁺	41 (40.2)	79 (72.5)	P < 0.001
*Treatment completed*	37 (36.3)	38 (34.9)
*Cure*	4 (3.9)	41 (37.6)
Treatment success [excluding those lost to follow up and defaulters]^	41 (53.2)	79 (89.8)	P < 0.001
Treatment failure	8 (7.8)	4 (3.7)
Relapse	5 (4.9)	2 (1.8)
Default	4 (3.9)	0
Lost to follow-up	21 (20.6)	21 (19.3)
Death	22 (21.6)	3 (2.8)	P < 0.001
Treatment modified	1 (1.0)	0

* Includes patients completing 24 months follow-up and those being labelled as death, lost to follow-up, failure and relapse – i.e. does not include patients still under active follow-up.
⁺ Sum of cure and treatment completed.
^ In this outcome, the 'default' and 'lost to follow up' groups have been removed from the cohort, so that for HIV + n = 77, and for HIV- n = 88.

ISSN: 1471-2334